Compile Data Set for Download or QSAR
Report error Found 311 Enz. Inhib. hit(s) with all data for entry = 10952
LigandPNGBDBM580934(US11492348, Compound (-)143)
Affinity DataIC50: 1nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580932(US11492348, Compound 143 | 5-(4-(chroman-4-ylsulfo...)
Affinity DataIC50: 1.70nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580933(US11492348, Compound (+)143)
Affinity DataIC50: 4.5nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580930(US11492348, Compound 142a | (S)-5-(6-morpholino-4-...)
Affinity DataIC50: 5.70nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580931(US11492348, Compound 142b | (R)-5-(6-morpholino-4-...)
Affinity DataIC50: 6.80nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580938(US11492348, Compound 147 | 5-(4-((2,3-dihydrobenzo...)
Affinity DataIC50: 7nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580921(US11492348, Compound 133 | 5-(4-(difluoro(tetrahyd...)
Affinity DataIC50: 12nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580939(US11492348, Compound 148 | 5-(6-morpholino-4-((tet...)
Affinity DataIC50: 13nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580926(US11492348, Compound 138 | (2-(2-aminopyrimidin-5-...)
Affinity DataIC50: 14nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580940(US11492348, Compound 149 | (2-(2-aminopyrimidin-5-...)
Affinity DataIC50: 14nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetRAC-alpha serine/threonine-protein kinase [1-472,474-480](Human)
Neuropore Therapies

US Patent
LigandPNGBDBM580927(US11492348, Compound 139 | 5-(4-((2-chlorophenyl)s...)
Affinity DataIC50: 16nMAssay Description:Inhibition of the PI3K-AKT-mTOR pathway was measured by quantifying the loss of (Ser-473) pAKT using AlphaScreen (Perkin Elmer). B103 (Rat Neuroblast...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580927(US11492348, Compound 139 | 5-(4-((2-chlorophenyl)s...)
Affinity DataIC50: 17nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580918(US11492348, Compound 130 | 5-(6-morpholino-4-((tet...)
Affinity DataIC50: 23nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580919(US11492348, Compound 131 | (2-(2-aminopyrimidin-5-...)
Affinity DataIC50: 23nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580917(US11492348, Compound 129 | (3-((2-(2-aminopyrimidi...)
Affinity DataIC50: 34nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580910(US11492348, Compound 122 | (2-(2-aminopyrimidin-5-...)
Affinity DataIC50: 37nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580911(US11492348, Compound 123 | 5-(4-(difluoro(phenyl)m...)
Affinity DataIC50: 46nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580856(US11492348, Compound 68 | 1-(3-((3-(2-aminopyrimid...)
Affinity DataIC50: 47nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580915(US11492348, Compound 127 | 5-(6-morpholino-4-(1- p...)
Affinity DataIC50: 56nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580929(US11492348, Compound 141 | 5-(4-(chroman-4-yl)-6-m...)
Affinity DataIC50: 62nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580869(US11492348, Compound 81 | 3-((3-(2-aminopyrimidin-...)
Affinity DataIC50: 62nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM580903(US11492348, Compound 115 | 5-(6-morpholino-4-(phen...)
Affinity DataIC50: 63nMAssay Description:The substrate was prepared in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580903(US11492348, Compound 115 | 5-(6-morpholino-4-(phen...)
Affinity DataIC50: 66nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580895(US11492348, Compound 107 | (R)-4-chloro-5-(3-morph...)
Affinity DataIC50: 67nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580922(US11492348, Compound 134 | 5-(4-(2-chlorophenoxy)-...)
Affinity DataIC50: 70nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580925(US11492348, Compound 137 | 5-(6-morpholino-4-(o-to...)
Affinity DataIC50: 75nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580923(US11492348, Compound 135 | 5-(4-(2-methoxyphenoxy)...)
Affinity DataIC50: 79nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580881(US11492348, Compound 93 | 3-((3-(2-aminopyrimidin-...)
Affinity DataIC50: 88nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580908(US11492348, Compound 120 | 5-(6-morpholino-4-pheno...)
Affinity DataIC50: 91nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580865(US11492348, Compound 77 | (3-((3-(2-aminopyrimidin...)
Affinity DataIC50: 100nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580894(US11492348, Compound 106 | (R)-4-fluoro-5-(3-morph...)
Affinity DataIC50: 100nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580811(US11492348, Compound 23 | 5-(3-(benzylsulfonyl)-5-...)
Affinity DataIC50: 100nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580882(US11492348, Compound 94 | 3-((3-(2-aminopyrimidin-...)
Affinity DataIC50: 110nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580841(US11492348, Compound 53 | (S)-5-(3-morpholino-5-((...)
Affinity DataIC50: 110nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580907(US11492348, Compound 119 | 5-(3-((2,3-dihydrobenzo...)
Affinity DataIC50: 110nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580928(US11492348, Compound 140 | 5-(4-(3,4-dihydroquinol...)
Affinity DataIC50: 120nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580912(US11492348, Compound 124 | 5-(4-benzyl-6-morpholin...)
Affinity DataIC50: 120nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580883(US11492348, Compound 95 | 3-((3-(2-aminopyrimidin-...)
Affinity DataIC50: 120nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580839(US11492348, Compound 51 | 5-(3-morpholino-5-((tetr...)
Affinity DataIC50: 120nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580840(US11492348, Compound 52 | (R)-5-(3-morpholino-5-((...)
Affinity DataIC50: 130nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM580915(US11492348, Compound 127 | 5-(6-morpholino-4-(1- p...)
Affinity DataIC50: 130nMAssay Description:The substrate was prepared in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580842(US11492348, Compound 54 | tert-butyl 3-((3-(2-amin...)
Affinity DataIC50: 130nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580880(US11492348, Compound 92 | 3-((3-(2-aminopyrimidin-...)
Affinity DataIC50: 150nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580879(US11492348, Compound 91 | 1-(3-((3-(2-aminopyrimid...)
Affinity DataIC50: 180nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580866(US11492348, Compound 78 | 1-(3-((3-(2-aminopyrimid...)
Affinity DataIC50: 180nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetRAC-alpha serine/threonine-protein kinase [1-472,474-480](Human)
Neuropore Therapies

US Patent
LigandPNGBDBM580926(US11492348, Compound 138 | (2-(2-aminopyrimidin-5-...)
Affinity DataIC50: 190nMAssay Description:Inhibition of the PI3K-AKT-mTOR pathway was measured by quantifying the loss of (Ser-473) pAKT using AlphaScreen (Perkin Elmer). B103 (Rat Neuroblast...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580913(US11492348, Compound 125 | 5-(6-morpholino-4-(1-ph...)
Affinity DataIC50: 210nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580867(US11492348, Compound 79 | (3-((3-(2-aminopyrimidin...)
Affinity DataIC50: 210nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580875(US11492348, Compound 87 | 5-(3-((difluoro(phenyl)m...)
Affinity DataIC50: 210nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM580863(US11492348, Compound 75 | 1-(3-((3-(2-aminopyrimid...)
Affinity DataIC50: 250nMAssay Description:Quantification of ATP to ADP conversion as a measure of PI3Kα activity. Active PI3Kα (Life Technologies), in the presence or absence of PI3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

Displayed 1 to 50 (of 311 total ) | Next | Last >>
Jump to: